Research Study: AEGIS II
Condition:
acute coronary syndrome
Study Sponsor: CSL Behring LLC
Study Investigator: Thomas Knickelbine, MD
Study Contact: Stephanie Ebnet, RN
stephanie.ebnet@allina.com
612-863-6286
Every research study comes with its own unique risks and benefits; the study team will assess whether you’re an eligible candidate and ensure you’re provided with all the information you need to decide if participating is right for you.
About this Study:

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed.
Eligibility Criteria:

  • Male or female least 18 years of age
  • Evidence of myocardial necrosis, consistent with type I (spontaneous) MI
  • No suspicion of acute kidney injury
  • Evidence of multivessel coronary artery disease
  • Presence of established cardiovascular risk factor(s):
    1. Diabetes mellitus on pharmacotherapy OR
    2. 2 or more of the following: age ≥ 65 years, prior history of MI, peripheral arterial disease

Interested in participating in this study?

Reach out to the study contact directly, or fill out this form and we will contact you and assess whether you are an eligible candidate!